Targeting_the_Source_of_Persistent_HIV_Viremia

持续性 HIV 病毒血症的目标来源

基本信息

  • 批准号:
    8047422
  • 负责人:
  • 金额:
    $ 25.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-15 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

Current antiretroviral therapy is not curative and does not eradicate HIV-1 viremia. Rather, the virus persists and is merely suppressed during therapy. The source and dynamics of this persistent viremia is currently unknown. Determining the source of persistent viremia during combination antiretroviral therapy will inform future efforts aimed at viral eradication. To address these important issues the current study puts forward two hypotheses. First, to identify the source of persistent viremia in patients on suppressive therapy we must compare HIV populations in patient plasma to the HIV populations found in the cerebrospinal fluid (CSF), cells from peripheral blood and cells isolated from other tissues. Second, activating the latently HIV-infected cell will induce the expression of the integrated HIV genome making it vulnerable to immune-mediated killing and therapy. To test these hypotheses we seek to achieve three specific aims. First, we will characterize the HIV-1 genetic populations in plasma, CSF and a broad spectrum of HIV-infected cells from peripheral blood, gut associated lymphoid tissue (GALT), lymph node tissue (LNT), and bone marrow tissue (BMT) from patients on suppressive therapy using such methods as single-genome sequencing and single-proviral sequencing. The phylogenetic relatedness of the plasma-derived viral RNA sequences and intracellular viral DNA sequences will be determined. The comparison of HIV populations from plasma to different cellular and tissue compartments will allow us to investigate and seek to identify the source and genetic dynamics of persistent viremia in patients on suppressive therapy. For our second aim, we will apply peer-reviewed and published ligation-based molecular tools known as proximity ligation probes to specifically label and measure HIV virions and identify the cellular source of these particles. This will be important for identifying the cell lineage producing virions during suppressive therapy. Third, we will use new inhibitors of DNA methylation, protein methylation or histone deacetylation to stimulate cellular HIV transcription and therefore release of HIV from latently infected memory CD4+ T-cells, making the virus vulnerable to antiretroviral drugs. To accomplish this aim, we will culture CD4+ memory T-cells from patients on suppressive therapy and expose these cells to the new inhibitors. This research plan will bring together a diverse, multinational group of experts from Europe and United States specializing in HIV translational research, HIV clinical treatment, molecular genetics, and antiviral drug development.
目前的抗逆转录病毒疗法不能治愈,也不能根除HIV-1病毒血症。相反,病毒会持续存在

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah Elizabeth Palmer其他文献

Sarah Elizabeth Palmer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sarah Elizabeth Palmer', 18)}}的其他基金

Combining immunogenic peptides and Nef blockade to enhance CD8 T-cell-mediated clearance of HIV-infected cells
结合免疫原性肽和 Nef 阻断来增强 CD8 T 细胞介导的 HIV 感染细胞清除
  • 批准号:
    10685405
  • 财政年份:
    2022
  • 资助金额:
    $ 25.03万
  • 项目类别:
Combining immunogenic peptides and Nef blockade to enhance CD8 T-cell-mediated clearance of HIV-infected cells
结合免疫原性肽和 Nef 阻断来增强 CD8 T 细胞介导的 HIV 感染细胞清除
  • 批准号:
    10482443
  • 财政年份:
    2022
  • 资助金额:
    $ 25.03万
  • 项目类别:
Genetic analysis of unspliced HIV RNA produced during HDAC inhibitor therapy
HDAC 抑制剂治疗期间产生的未剪接 HIV RNA 的遗传分析
  • 批准号:
    8730254
  • 财政年份:
    2014
  • 资助金额:
    $ 25.03万
  • 项目类别:
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms
HAART 治疗患者中的病毒库和庇护所:作用和机制
  • 批准号:
    8202570
  • 财政年份:
    2011
  • 资助金额:
    $ 25.03万
  • 项目类别:
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms
HAART 治疗患者中的病毒库和庇护所:作用和机制
  • 批准号:
    8500171
  • 财政年份:
  • 资助金额:
    $ 25.03万
  • 项目类别:
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms
HAART 治疗患者中的病毒库和庇护所:作用和机制
  • 批准号:
    8376036
  • 财政年份:
  • 资助金额:
    $ 25.03万
  • 项目类别:
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms
HAART 治疗患者中的病毒库和庇护所:作用和机制
  • 批准号:
    8892978
  • 财政年份:
  • 资助金额:
    $ 25.03万
  • 项目类别:
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms
HAART 治疗患者中的病毒库和庇护所:作用和机制
  • 批准号:
    8703600
  • 财政年份:
  • 资助金额:
    $ 25.03万
  • 项目类别:

相似海外基金

Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
  • 批准号:
    9348616
  • 财政年份:
    2016
  • 资助金额:
    $ 25.03万
  • 项目类别:
Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
  • 批准号:
    9212055
  • 财政年份:
    2016
  • 资助金额:
    $ 25.03万
  • 项目类别:
A CONFERENCE ON THE 'CRISIS' OF ACADEMIC MEDICAL CENTERS
关于学术医疗中心“危机”的会议
  • 批准号:
    6335654
  • 财政年份:
    2000
  • 资助金额:
    $ 25.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了